Masitinib for ALS: AB10015 Reports 42.3% 5-Year Survival
A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. The number is large for ALS, but the long-term comparison is historical and modeled rather than randomized placebo follow-up.1 Research Highlights 42.3% reached 5 years from onset: Ludolph et al. …
